In vitro activity of curcumin in combination with epigallocatechin gallate (EGCG) versus multidrug-resistant Acinetobacter baumannii

被引:78
作者
Betts, Jonathan W. [1 ]
Wareham, David W. [1 ,2 ]
机构
[1] Queen Mary Univ London, Antimicrobial Res Grp, Ctr Immunol & Infect Dis, Blizard Inst, London E1 2AT, England
[2] Barts Hlth NHS Trust, Div Infect, London E1 2ES, England
来源
BMC MICROBIOLOGY | 2014年 / 14卷
关键词
Curcumin; Epigallocatechin gallate; Acinetobacter baumannii; Synergy; Antibacterial; ANTIMICROBIAL ACTIVITY; HYDROGEN-PEROXIDE; TEA POLYPHENOL; GREEN TEA; SYNERGY; (-)-EPIGALLOCATECHIN-3-GALLATE; BIOAVAILABILITY; EPICATECHIN; THEAFLAVIN; MECHANISM;
D O I
10.1186/1471-2180-14-172
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Background: Acinetobacter baumannii is an opportunistic human pathogen often associated with life-threatening infections in the immunocompromised and the critically ill. Strains are often multidrug-resistant (MDR) and due to the lack of new synthetic antimicrobials in development for treatment, attention is increasingly focused on natural compounds either as stand-alone or adjunctive agents. Curcumin (CCM) is a natural polyphenol found in turmeric and isolated from the plant, Curcuma longa. Curcumin has been found to possess many biological properties, including antibacterial activity. In this study the antimicrobial activity of CCM and synergistic effects with epigallocatechin gallate (EGCG) against multidrug-resistant strains of A. baumannii were investigated and assessed via checkerboard and time-kill assays. Results: The MIC of CCM was > 256 mu g/mL against all strains of A. baumannii whilst those for EGCG ranged from 128-1024 mu g/mL. In checkerboard studies synergy was observed against 5/9 isolates, with an additive effect noted in the remaining 4. The addition of EGCG reduced the MIC of CCM by 3- to 7-fold, with the greatest interaction resulting in a CCM MIC of 4 mu g/mL. Time-kill curves indicated that a CCM-EGCG (1:8 and 1:4) combination was bactericidal with a 4 to 5-log reduction in viable counts after 24 h compared to the most effective polyphenol alone. Conclusions: This study demonstrates that despite little antibacterial activity alone, CCM activity is greatly enhanced in the presence of EGCG resulting in antibacterial activity against MDR A. baumannii. The combination may have a potential use in medicine as a topical agent to prevent or treat A. baumannii infections.
引用
收藏
页数:5
相关论文
共 50 条
  • [21] Antibiofilm activity of an EDTA-containing nanoemulsion on multidrug-resistant Acinetobacter baumannii
    Ramalingam, Karthikeyan
    Lee, Valerie A.
    ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY, 2018, 46 : 737 - 743
  • [22] Mutant prevention concentration of colistin alone and in combination with rifampicin for multidrug-resistant Acinetobacter baumannii
    Nordqvist, H.
    Nilsson, L. E.
    Claesson, C.
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2016, 35 (11) : 1845 - 1850
  • [23] Confronting multidrug-resistant Acinetobacter baumannii: a review
    Neonakis, Ioannis K.
    Spandidos, Demetrios A.
    Petinaki, Efthimia
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2011, 37 (02) : 102 - 109
  • [24] Bacteriophage Indie resensitizes multidrug-resistant Acinetobacter baumannii to antibiotics in vitro
    Orozco-Ochoa, Alma Karen
    Gonzalez-Gomez, Jean Pierre
    Quinones, Beatriz
    Castro-del Campo, Nohelia
    Valdez-Torres, Jose Benigno
    Chaidez-Quiroz, Cristobal
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [25] Antibiotic Activity of Wickerhamomyces anomalus Mycocins on Multidrug-Resistant Acinetobacter baumannii
    Junges, Daniele S. B.
    Delabeneta, Mateus F.
    Rosseto, Lana Rubia B.
    Nascimento, Bruna L.
    Paris, Ana Paula
    Persel, Cristiane
    Loth, Eduardo A.
    Simao, Rita C. G.
    Menolli, Rafael A.
    Paula, Claudete R.
    Gandra, Rinaldo F.
    MICROBIAL ECOLOGY, 2020, 80 (02) : 278 - 285
  • [26] A New Combination of a Pleuromutilin Derivative and Doxycycline for Treatment of Multidrug-Resistant Acinetobacter baumannii
    Siricilla, Shajila
    Mitachi, Katsuhiko
    Yang, Junshu
    Eslamimehr, Shakiba
    Lemieux, Maddie R.
    Meibohm, Bernd
    Ji, Yinduo
    Kurosu, Michio
    JOURNAL OF MEDICINAL CHEMISTRY, 2017, 60 (07) : 2869 - 2878
  • [27] Comparative metabolomics reveals key pathways associated with the synergistic activity of polymyxin B and rifampicin combination against multidrug-resistant Acinetobacter baumannii
    Zhao, Jinxin
    Han, Mei-Ling
    Zhu, Yan
    Lin, Yu-Wei
    Wang, Yi-Wen
    Lu, Jing
    Hu, Yang
    Zhou, Qi Tony
    Velkov, Tony
    Li, Jian
    BIOCHEMICAL PHARMACOLOGY, 2021, 184
  • [28] Multidrug-resistant Acinetobacter baumannii: a challange for current therapeutic
    Barletta Farias, Roberto Carlos
    Perez Ponce, Leonardo Javier
    Castro Vega, Gabriela
    Pujol Perez, Misael
    Barletta del Castillo, Jorge Emilio
    Duenas Perez, Yeny
    MEDISUR-REVISTA DE CIENCIAS MEDICAS DE CIENFUEGOS, 2018, 16 (02): : 322 - 334
  • [29] Drug treatment for multidrug-resistant Acinetobacter baumannii infections
    Bassetti, Matteo
    Righi, Elda
    Esposito, Silvano
    Petrosillo, Nicola
    Nicolini, Laura
    FUTURE MICROBIOLOGY, 2008, 3 (06) : 649 - 660
  • [30] Multidrug-resistant Acinetobacter baumannii as an emerging concern in hospitals
    Ibrahim, Susan
    Al-Saryi, Nadal
    Al-Kadmy, Israa M. S.
    Aziz, Sarah Naji
    MOLECULAR BIOLOGY REPORTS, 2021, 48 (10) : 6987 - 6998